February, marked globally as Cancer Prevention Month, is a time to renew our commitment to reducing the impact of cancer. This month serves as a reminder of the significant strides made in cancer research, treatment, and prevention. However, it also underscores the need for continued vigilance and...

In order to live better, you’ve got to breathe better. October is Healthy Lung Month, so let’s explore all the ways in which we can keep our lungs healthy and breathe easier. Key takeaways:  Lungs are an essential organ and the focal point of the respiratory...

Cancer can present itself in many ways and has varying and debilitating symptoms. However, some forms of cancer are chronic and could pose more challenges regarding health care management. Cancer is a serious condition with various causes, and different types of cancer affect people differently....

Inflation directly affects the prices of prescription drugs in the U.S., but the Inflation Reduction Act can help combat the soaring prices and make them accessible to patients. According to a 2022 survey , one in three adults says they haven’t taken prescription medications due to the...

Among white and Hispanic people born after 1965, rates of lung cancer are now higher in women than men, according to researchers from the American Cancer Society and National Cancer Institute.  The study, published last month in the New England Journal of Medicine, revealed an overall decline...

The US Food and Drug Administration (FDA) has approved the protein kinase inhibitor Tagrisso (osimertinib) as a first-line treatment option for certain patients with metastatic non-small cell lung carcinoma (NSCLC). Earlier this month, AstraZeneca presented new data from a Phase III FLAURA trial...

The US Food and Drug Administration (FDA) has expanded the approval of Imfinzi (durvalumab) to provide a therapy to slow the progression of cancer in certain patients with non-small cell lung cancer (NSCLC). AstraZeneca first gained accelerated FDA approval for Imfinzi in May 2017. Imfinzi is an...

The US Food and Drug Administration (FDA) has granted breakthrough therapy (BTD) designation to the AstraZeneca drug Tagrisso (osimertinib).  It is the sixth such designation granted to AstraZeneca oncology medicine since 2014. Tagrisso received BTD for first-line treatment of patients with...

The US Food & Drug Administration's (FDA) decision to approve a medication to treat patients whose cancer has a specific genetic feature, or biomarker, has been hailed as an "important first" in the fight against the disease. Keytruda (pembrolizumab) is a monoclonal antibody already in use to...

Non-small cell lung cancer (NSCLC) patients have a new treatment available following the US Food & Drug Administration's (FDA's) approval of Alunbrig (brigatinib). The Takeda Pharmaceuticals medication received Accelerated Approval for treatment of patients with anapestic lymphoma...